Do you have any questions?
Don't hesitate to contact us. We are happy to answer your questions.
Events
Explore our upcoming congresses and events to find out when we are in a city or area near you. Or check out our archived posters and presentation abstracts below.
Upcoming Event: 18th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
We are excited to be present at the 18-ICML, 2025 and look forward to welcoming you to our booth. Meet our team to find out more about our clinical program or join the DALY II US oral presentations during the new cellular therapies and CNS lymphomas sessions.
Find out moreUpcoming Event: 18th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
We are excited to be present at the 18-ICML, 2025 and look forward to welcoming you to our booth. Meet our team to find out more about our clinical program or join the DALY II US oral presentations during the new cellular therapies and CNS lymphomas sessions.
Find out moreConferences and events calendar
Upcoming events
30th EHA Congress
June 12th - 15th 2025 | Milan, Italy
18th ICML (international conference on malignant lymphoma)
June 17th - 21th 2025 | Lugano, Switzerland
DGHO (Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie 2025)
October 24th - 27th 2025 | Cologne, Germany
Past events
EBMT 51st Annual Meeting
March 30th - April 2nd 2025 | Florence, Italy
Tandem Meetings-Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
February 12th - 16th 2025 | Honolulu, USA
EHA-EBMT 7th European CAR T-cell Meeting
February 6th - 8th 2025 | Strasbourg, France
ASH – 66th American Society of Hematology Annual Meeting and Exposition 2024
December 7th - 10th 2024 | San Diego, USA
EHA - European Hematology Association Hybrid Congress
June 13th - 16th 2024 | Madrid, Spain
50th Annual Meeting of the EBMT
April 14th - 17th 2024 | Glasgow, Scotland
2024 Tandem Meetings of ASTCT™ and CIBMTR®
February 21th - 25th 2023 | San Antonio, Texas, USA
ASH – 65th American Society of Hematology Annual Meeting and Exposition 2023
December 9th-12th 2023 | San Diego, USA
DGHO 2023 – Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
October 13th - 16th 2023 | Hamburg, Germany
ESCHART 2023 – 2nd How I Manage CAR-T Therapies and Bispecific Antibodies for my patients
September 29th - October 1st 2023 | Berlin, Germany
17thICML – International Conference on Malignant Lymphoma
June 13rd - 17th 2023 | Lugano, Switzerland | hybrid event
EHA 2023 – European Hematology Association
June 8th - 11th 2023 | Frankfurt, Germany
EBMT – European Society for Blood and Marrow Transplantation 49th Annual Meeting 2023
April 23rd - 26th 2023 | Paris, France
2023 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
February 15th - 19th 2023 | Orlando, USA
EBMT – EHA 5th European CAR T-cell Meeting
February 9th - 11th 2023 | Rotterdam, Netherlands
CTI – Cell Therapy Innovation 360
January 25th - 26th 2023 | Lyon, France
ASH – 64th American Society of Hematology Annual Meeting and Exposition 2022
December 10th - 13th 2022 | New Orleans, USA
Latest resources from Miltenyi Biomedicine
View recent posters, presentations and press releases
Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | presentation slides
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (zamto-cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
ASH24 | presentation slides
Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting
ASH 2024 | press release
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract